DISCONTINUATION OF INFLIXIMAB THERAPY IN PATIENTS WITH CROHN’S DISEASE IN SUSTAINED, COMBINED CLINICAL-BIOCHEMICAL-ENDOSCOPIC REMISSION: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED CLINICAL TRIAL

Sine Buhl ¹ Casper Steenholdt ¹ Jørn Brynskov ¹ Katrine Risager Christensen ¹ Maria Dorn-Rasmussen ¹ Ole Østergaard Thomsen ¹ Klaus Bendtzen ¹ Tobias Wirenfeldt Klausen ¹ Jens Frederik Dahlerup ² Niels Thorsgaard ³ Jørgen Jahnsen ⁴ akbar molazahi ⁵ Natalia Pedersen ⁶ jens kjeldsen ⁷ Sven Almer ⁸ Eva Efsen Dahl ⁹ Ida Vind ¹⁰ Annett Cannon ¹¹ Jan Marsal ¹² Taina Sipponen ¹³ Jørgen Agnholt ¹³ Hendrika Adriana Linda Kievit ¹³ Synnøve Louise Aure ¹³ Lars Martin Martinsen ¹⁴ Jane Møller Hansen ¹⁴ Mark Andrew Ainsworth ¹⁴
¹ Copenhagen University Hospital at Herlev, Herlev, Denmark
² Aarhus University Hospital, Aarhus, Denmark
³ Herning Regional Hospital, Herning, Denmark
⁴ Akershus University Hospital, Lørenskog, Norway
⁵ Nykøbing Falster Hospital, Nykøbing F, Denmark
⁶ Slagelse Hospital, Slagelse, Denmark
⁷ Odense University Hospital, Odense, Denmark
⁸ Karolinska University Hospital, Stockholm, Sweden
⁹ Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark
¹⁰ Hvidovre Hospital, Hvidovre, Denmark
¹¹ Silkeborg Regional Hospital, Silkeborg, Denmark
¹² Skånes Universitetssjukhus, Lund, Sweden
¹³ Helsinki University Hospital, Helsinki, Finland
¹⁴ Thisted Hospital, Thisted, Denmark

Topic
IBD, Immunology

Session
IBD: Clinical trials IV

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)

Do you need help setting up your myUEG account?
Contact us at [email protected]

Social Sharing